Modality
Small Molecule
MOA
STINGag
Target
CD19
Pathway
Innate Imm
HCC
Development Pipeline
Preclinical
~Jun 2021
→ ~Sep 2022
Phase 1
Dec 2022
→ Aug 2028
Phase 1Current
NCT08585196
147 pts·HCC
2022-12→2028-08·Completed
147 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-08-142.4y awayPh2 Data· HCC
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1/2
Complet…
Catalysts
Ph2 Data
2028-08-14 · 2.4y away
HCC
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08585196 | Phase 1/2 | HCC | Completed | 147 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-8662 | Pfizer | NDA/BLA | CD19 | |
| RHH-5389 | Roche | Preclinical | RET | |
| NVS-6974 | Novartis | Preclinical | CD19 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| SNY-5783 | Sanofi | Phase 1/2 | MET | |
| DSN-1421 | Daiichi Sankyo | Phase 3 | Nectin-4 | |
| GIL-4361 | Gilead Sciences | Preclinical | PCSK9 | |
| INC-5849 | Incyte | Phase 2 | PCSK9 |